Get the Stockscreener App
19.59
5.00%
-1.03
Dianthus Therapeutics Inc stock is traded at $19.59, with a volume of 209.70K.
It is down -5.00% in the last 24 hours and up +19.96% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$20.62
Open:
$21.25
24h Volume:
209.70K
Relative Volume:
0.64
Market Cap:
$697.13M
Revenue:
$4.12M
Net Income/Loss:
$-56.68M
P/E Ratio:
-3.5343
EPS:
-5.5429
Net Cash Flow:
$-51.44M
1W Performance:
-9.72%
1M Performance:
+19.96%
6M Performance:
-32.59%
1Y Performance:
-21.42%
1-Day Range:
$19.35
$21.39
1-Week Range:
$19.35
$22.12
52-Week Range:
$13.37
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
19.59 | 697.13M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Avidity Partners Management LP Lowers Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by Braidwell LP - MarketBeat
106,434 Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Bought by Ally Bridge Group NY LLC - MarketBeat
5AM Venture Management LLC Sells 203,908 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Wells Fargo & Company MN Sells 8,271 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Allostery Investments LP Buys New Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (DNTH) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $54.33 - MarketBeat
Barclays PLC Raises Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
180,000 Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Acquired by Adage Capital Partners GP L.L.C. - MarketBeat
Dianthus Therapeutics completes enrollment for MaGic trial - Investing.com Australia
Dianthus Therapeutics completes enrollment for MaGic trial By Investing.com - Investing.com Canada
Dianthus Therapeutics Inc expected to post a loss of 85 cents a shareEarnings Preview - TradingView
Breakthrough gMG Treatment DNTH103 Hits Major Milestone: Phase 2 Results Coming This Fall - Stock Titan
Invesco Ltd. Purchases 790 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus (DNTH) Completes Enrollment for Phase 2 MaGic Trial | D - GuruFocus
TCG Crossover Management LLC Takes Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
JPMorgan Chase & Co. Increases Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap DownHere's What Happened - MarketBeat
Legal & General Group Plc Buys 2,363 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
BlackRock, Inc. Reduces Stake in Dianthus Therapeutics Inc. - GuruFocus
Dianthus Therapeutics to Participate in Two Upcoming Investor Events - The Manila Times
Dianthus Therapeutics Reveals Growth Strategy at Two Elite Healthcare Investment Forums - Stock Titan
Dianthus Therapeutics (DNTH) Sees Rise in Short Interest Despite Stock Rebound | DNTH Stock News - GuruFocus
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.4%Time to Buy? - MarketBeat
Bain Capital Life Sciences Investors LLC Sells 323,716 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Walleye Capital LLC Purchases 52,890 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead - Seeking Alpha
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Bought by Geode Capital Management LLC - Defense World
Fmr LLC Purchases 36,133 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Vanguard Group Inc. Sells 20,331 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
A stock that deserves closer examination: Dianthus Therapeutics Inc (DNTH) - uspostnews.com
Wellington Management Group LLP Boosts Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
KLP Kapitalforvaltning AS Acquires New Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Corebridge Financial Inc. - Defense World
Alliancebernstein L.P. Purchases 136,633 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):